Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

MoonLake Immunotherapeutics (MLTX) EBT (2021 - 2026)

MoonLake Immunotherapeutics' EBT history spans 6 years, with the latest figure at -$69.1 million for Q1 2026.

  • Quarterly EBT fell 70.98% to -$69.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$258.4 million through Mar 2026, down 75.22% year-over-year, with the annual reading at -$229.7 million for FY2025, 89.9% down from the prior year.
  • EBT came in at -$69.1 million for Q1 2026, down from -$62.8 million in the prior quarter.
  • In the past five years, EBT ranged from a high of -$7.8 million in Q4 2023 to a low of -$70.6 million in Q3 2025.
  • The 5-year median for EBT is -$17.4 million (2022), against an average of -$31.1 million.
  • The largest YoY upside for EBT was 69.32% in 2022 against a maximum downside of 20705.61% in 2022.
  • MoonLake Immunotherapeutics' EBT stood at -$16.5 million in 2022, then surged by 52.34% to -$7.8 million in 2023, then plummeted by 491.0% to -$46.4 million in 2024, then crashed by 35.41% to -$62.8 million in 2025, then fell by 10.06% to -$69.1 million in 2026.
  • Per Business Quant, the three most recent readings for MLTX's EBT are -$69.1 million (Q1 2026), -$62.8 million (Q4 2025), and -$70.6 million (Q3 2025).